

### Remarks

The specification has been amended as set forth above to add a claim for priority to the application.


The amendments to the claims presented herewith are made with respect to the claims as presented with the International Preliminary Examination Report ("IPER") accompanying this amendment. Upon entry of the above amendments, the claims pending will be claims 1-6 and 16-28.

The amendments to claims 1, 4, and 6 concern minor informalities or removal of multiple dependencies. New claim 16 finds descriptive support in original claim 6. New claims 17-25 find descriptive support throughout the specification and, particularly, in claims 1-6 and 11 of the priority PCT application as filed. New claims 17-25 differ from the corresponding PCT claims in that reference to atherosclerosis has been deleted and the definition of GHRPs has been restricted to those that are devoid of GH-secreting activity *in vivo*, the latter limitation finding descriptive support at page 9 of the specification (first full paragraph). New claims 26-28 find descriptive support in claims 13-15 as presented with the IPER. For these reasons, no new matter has been entered by way of these amendments.

Applicants hereby request entry into the National stage and examination of the above-identified application in its entirety.

Respectfully submitted,

Date: February 22, 2005

  
\_\_\_\_\_  
Edwin V. Merkel  
Registration No. 40,087

NIXON PEABODY LLP  
Clinton Square, P.O. Box 31051  
Rochester, New York 14603-1051  
Telephone: (585) 263-1128  
Facsimile: (585) 263-1600